489 related articles for article (PubMed ID: 24160757)
1. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.
Stout SM; Cimino NM
Drug Metab Rev; 2014 Feb; 46(1):86-95. PubMed ID: 24160757
[TBL] [Abstract][Full Text] [Related]
2. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
Qian Y; Gurley BJ; Markowitz JS
J Clin Psychopharmacol; 2019; 39(5):462-471. PubMed ID: 31433338
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.
Nasrin S; Watson CJW; Perez-Paramo YX; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1070-1080. PubMed ID: 34493602
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Bansal S; Zamarripa CA; Spindle TR; Weerts EM; Thummel KE; Vandrey R; Paine MF; Unadkat JD
Clin Pharmacol Ther; 2023 Sep; 114(3):693-703. PubMed ID: 37313955
[TBL] [Abstract][Full Text] [Related]
5. Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.
Bansal S; Maharao N; Paine MF; Unadkat JD
Drug Metab Dispos; 2020 Oct; 48(10):1008-1017. PubMed ID: 32587099
[TBL] [Abstract][Full Text] [Related]
6. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity.
Yamaori S; Koeda K; Kushihara M; Hada Y; Yamamoto I; Watanabe K
Drug Metab Pharmacokinet; 2012; 27(3):294-300. PubMed ID: 22166891
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites.
Qian Y; Wang X; Markowitz JS
Drug Metab Dispos; 2019 May; 47(5):465-472. PubMed ID: 30833288
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.
Bansal S; Paine MF; Unadkat JD
Drug Metab Dispos; 2022 Apr; 50(4):351-360. PubMed ID: 35115300
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes.
Watanabe K; Yamaori S; Funahashi T; Kimura T; Yamamoto I
Life Sci; 2007 Mar; 80(15):1415-9. PubMed ID: 17303175
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization.
Doohan PT; Oldfield LD; Arnold JC; Anderson LL
AAPS J; 2021 Jun; 23(4):91. PubMed ID: 34181150
[TBL] [Abstract][Full Text] [Related]
11. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes.
Yamaori S; Kushihara M; Yamamoto I; Watanabe K
Biochem Pharmacol; 2010 Jun; 79(11):1691-8. PubMed ID: 20117100
[TBL] [Abstract][Full Text] [Related]
12. Identification of the human liver cytochrome P450 isoenzymes responsible for the 5-methylhydroxylation of the novel anti-fibrotic drug AKF-PD.
He X; Luo X; Liu Z; Hu G; Cheng Z
Xenobiotica; 2011 Oct; 41(10):844-50. PubMed ID: 21679010
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites.
Nasrin S; Watson CJW; Bardhi K; Fort G; Chen G; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1081-1089. PubMed ID: 34493601
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.
Anderson GD; Chan LN
Clin Pharmacokinet; 2016 Nov; 55(11):1353-1368. PubMed ID: 27106177
[TBL] [Abstract][Full Text] [Related]
15. Phytochemical Comparison of Medicinal Cannabis Extracts and Study of Their CYP-Mediated Interactions with Coumarinic Oral Anticoagulants.
Treyer A; Reinhardt JK; Eigenmann DE; Oufir M; Hamburger M
Med Cannabis Cannabinoids; 2023; 6(1):21-31. PubMed ID: 36814687
[TBL] [Abstract][Full Text] [Related]
16. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.
Yamaori S; Ebisawa J; Okushima Y; Yamamoto I; Watanabe K
Life Sci; 2011 Apr; 88(15-16):730-6. PubMed ID: 21356216
[TBL] [Abstract][Full Text] [Related]
17. Effects of cannabidiol and Δ
Smith SA; Le GH; Teopiz KM; Kwan ATH; Rhee TG; Ho RC; Wu J; Cao B; Ceban F; McIntyre RS
Drug Metab Rev; 2024; 56(2):164-174. PubMed ID: 38655747
[TBL] [Abstract][Full Text] [Related]
18. A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers.
Stott C; White L; Wright S; Wilbraham D; Guy G
Springerplus; 2013 Dec; 2(1):236. PubMed ID: 23750331
[TBL] [Abstract][Full Text] [Related]
19. 3H-delta 9-Tetrahydrocannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain.
Alozie SO; Martin BR; Harris LS; Dewey WL
Pharmacol Biochem Behav; 1980 Feb; 12(2):217-21. PubMed ID: 6246544
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450-mediated metabolism of the synthetic cannabinoids UR-144 and XLR-11.
Nielsen LM; Holm NB; Olsen L; Linnet K
Drug Test Anal; 2016 Aug; 8(8):792-800. PubMed ID: 26360322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
